News about Clinical Trials

Eli Lilly and Company's Omvoh Shows 4-Year Disease Clearance in Ulcerative Colitis

Eli Lilly and Company’s Omvoh (mirikizumab-mrkz), the first IL-23p19 inhibitor, shows durable disease clearance in ulcerative colitis, with more than 60 percent of patients maintaining remission through 4 years in the LUCENT-3 study.

Clinical Trials | 06/05/2026 | By News Bureau |  118

Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118

Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.

Clinical Trials | 05/05/2026 | By News Bureau |  101

Ascidian Therapeutics Completes STELLAR Trial Dose Escalation for ACDN-01 in Stargardt Disease

Ascidian Therapeutics completes Phase 1/2 STELLAR dose escalation for ACDN-01 in Stargardt disease, advances pediatric enrollment, and launches STARPATH prescreening to accelerate clinical trial access.

Clinical Trials | 05/05/2026 | By News Bureau |  121

Newron Pharmaceuticals Pauses US Enrollment in ENIGMA-TRS 2 Study

Newron Pharmaceuticals pauses enrolment at US sites in ENIGMA-TRS 2 study, while global ENIGMA-TRS 1 trial continues with more than 400 patients enrolled.

Clinical Trials | 02/05/2026 | By News Bureau

Sonire Therapeutics Launches First US Trial of HIFU Therapy for Pancreatic Cancer

Sonire Therapeutics begins US clinical testing of its HIFU platform, aiming to improve outcomes in hard-to-treat pancreatic cancer.

Clinical Trials | 01/05/2026 | By News Bureau

Vensica Medical Secures US FDA Clearance to Advance Needle-Free OAB Therapy to Phase II

Vensica Medical moves forward with clinical trials of its needle-free drug delivery platform aimed at improving access and patient comfort in overactive bladder treatment.

Clinical Trials | 01/05/2026 | By News Bureau

Pfizer's ELREXFIO Boosts Progression-Free Survival in Relapsed Multiple Myeloma

Pfizer’s ELREXFIO meets primary endpoint in MagnetisMM-5, showing significant progression-free survival benefit in relapsed/refractory multiple myeloma, with consistent safety and ongoing evaluation of Overall Survival (OS).

Clinical Trials | 01/05/2026 | By News Bureau

Precision BioSciences Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Trial

Precision BioSciences activates its first clinical site at Arkansas Children’s Hospital and begins patient enrollment in the phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy.

Clinical Trials | 30/04/2026 | By News Bureau

Argo Biopharma Doses First Patient in Phase 1 Trial of siRNA Drug BW-50218

Argo Biopharma doses first patient in Phase 1 trial of BW-50218, an siRNA therapeutic from its RADS platform designed for potent, durable gene silencing with targeted hepatic delivery and improved safety.

Clinical Trials | 29/04/2026 | By News Bureau

Soligenix Reports Phase 3 FLASH2 Interim Results for HyBryte in Cutaneous T-Cell Lymphoma

Soligenix reports Phase 3 FLASH2 interim results for HyBryte in Cutaneous T-Cell Lymphoma, with the study recommended for early termination due to futility.

Clinical Trials | 29/04/2026 | By News Bureau